These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 7319902)

  • 1. Osteoclast formation in response to intraperitoneal injection of 1 alpha-hydroxycholecalciferol in mice.
    Tinkler SM; Williams DM; Johnson NW
    J Anat; 1981 Aug; 133(Pt 1):91-7. PubMed ID: 7319902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of osteoclast formation: the significance of blood monocytes as osteoclast precursors during 1 alpha-hydroxycholecalciferol-stimulated bone resorption in the mouse.
    Tinkler SM; Williams DM; Linder JE; Johnson NW
    J Anat; 1983 Sep; 137 (Pt 2)(Pt 2):335-40. PubMed ID: 6630044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formation of osteoclasts from blood monocytes during 1 alpha-OH Vit D-stimulated bone resorption in mice.
    Tinkler SM; Linder JE; Williams DM; Johnson NW
    J Anat; 1981 Oct; 133(Pt 3):389-96. PubMed ID: 7328045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts.
    Marshall MJ; Wilson AS; Davie MW
    J Bone Miner Res; 1990 Sep; 5(9):955-62. PubMed ID: 2281826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the osteoclast in cranial suture waveform patterning.
    Byron CD
    Anat Rec A Discov Mol Cell Evol Biol; 2006 May; 288(5):552-63. PubMed ID: 16604542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Osteoclast formation in bone marrow cultures from two inbred strains of mice with different bone densities.
    Linkhart TA; Linkhart SG; Kodama Y; Farley JR; Dimai HP; Wright KR; Wergedal JE; Sheng M; Beamer WG; Donahue LR; Rosen CJ; Baylink DJ
    J Bone Miner Res; 1999 Jan; 14(1):39-46. PubMed ID: 9893064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Melatonin at pharmacologic doses increases bone mass by suppressing resorption through down-regulation of the RANKL-mediated osteoclast formation and activation.
    Koyama H; Nakade O; Takada Y; Kaku T; Lau KH
    J Bone Miner Res; 2002 Jul; 17(7):1219-29. PubMed ID: 12096835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CD44 deficiency on in vitro and in vivo osteoclast formation.
    de Vries TJ; Schoenmaker T; Beertsen W; van der Neut R; Everts V
    J Cell Biochem; 2005 Apr; 94(5):954-66. PubMed ID: 15578568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pamidronate prevents bone loss associated with carrageenan arthritis by reducing resorptive activity but not recruitment of osteoclasts.
    Moran EL; Fornasier TL; Bogoch TR
    J Orthop Res; 2000 Nov; 18(6):873-81. PubMed ID: 11192246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Femoral peak bone mass and osteoclast number in an animal model of age-related spontaneous osteopenia.
    Okamoto Y; Takahashi K; Toriyama K; Takeda N; Kitagawa K; Hosokawa M; Takeda T
    Anat Rec; 1995 May; 242(1):21-8. PubMed ID: 7604978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An assay system utilizing devitalized bone for assessment of differentiation of osteoclast progenitors.
    Amano S; Hanazawa S; Kawata Y; Ohta K; Kitami H; Kitano S
    J Bone Miner Res; 1992 Mar; 7(3):321-8. PubMed ID: 1585834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoclastogenesis is repressed by mechanical strain in an in vitro model.
    Rubin J; Fan X; Biskobing DM; Taylor WR; Rubin CT
    J Orthop Res; 1999 Sep; 17(5):639-45. PubMed ID: 10569471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macrophage colony stimulating factor increases bone resorption in dispersed osteoclast cultures by increasing osteoclast size.
    Lees RL; Heersche JN
    J Bone Miner Res; 1999 Jun; 14(6):937-45. PubMed ID: 10352102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone resorption inhibitor alendronate normalizes the reduced bone thickness of TRPV5(-/-) mice.
    Nijenhuis T; van der Eerden BC; Hoenderop JG; Weinans H; van Leeuwen JP; Bindels RJ
    J Bone Miner Res; 2008 Nov; 23(11):1815-24. PubMed ID: 18597625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cyclic vs. daily treatment with human parathyroid hormone (1-34) on murine bone structure and cellular activity.
    Iida-Klein A; Lu SS; Cosman F; Lindsay R; Dempster DW
    Bone; 2007 Feb; 40(2):391-8. PubMed ID: 17056311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor necrosis factor prevents alendronate-induced osteoclast apoptosis in vivo by stimulating Bcl-xL expression through Ets-2.
    Zhang Q; Badell IR; Schwarz EM; Boulukos KE; Yao Z; Boyce BF; Xing L
    Arthritis Rheum; 2005 Sep; 52(9):2708-18. PubMed ID: 16142752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblast and osteoclast cell number and cell activity in postmenopausal osteoporosis.
    Gruber HE; Ivey JL; Thompson ER; Chesnut CH; Baylink DJ
    Miner Electrolyte Metab; 1986; 12(4):246-54. PubMed ID: 3762511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The distribution of nuclei in imprints of feline osteoclasts.
    Addison WC
    J Anat; 1979 Aug; 129(Pt 1):63-8. PubMed ID: 511772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Src inhibitor AZD0530 reversibly inhibits the formation and activity of human osteoclasts.
    de Vries TJ; Mullender MG; van Duin MA; Semeins CM; James N; Green TP; Everts V; Klein-Nulend J
    Mol Cancer Res; 2009 Apr; 7(4):476-88. PubMed ID: 19372577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.